Guangzhou, China– August , 2024 – Inc. “The EC approval of BAT2206 is anothersignificant accomplishment for Bio-Thera as it marks Bio-Thera’s third EC approvedproduct” said Shengfeng Li, CEO at Bio-Thera. “Bio-Thera is committed toexpanding access fo...
View DetailsGUANGZHOU, and BEIJING, China and CAMBRIDGE, Mass, Aug 24, 2020 – Bio-Thera Solutions,Ltd.,a commercial stage biopharmaceutical company (688177.SH) and BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), today announced that the companies have executeda licen...
GUANGZHOU, China & MOSCOW--(BUSINESS WIRE)--Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and a pipeline of biosimilars, today announced the company has reached a licensing...
GUANGZHOU, China--(BUSINESS WIRE "BAT1706 is the company's second application for marketing approval of a Biosimilar in China, following the approval of Qletli® (adalimumab injection)," said Dr. Li Shengfeng, founder and CEO of Bio-TheraSolutions. "L...
